Black Titan (NASDAQ:BTTC – Get Free Report) and Oblong (NASDAQ:OBLG – Get Free Report) are both small-cap services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Institutional and Insider Ownership
2.0% of Oblong shares are owned by institutional investors. 0.7% of Black Titan shares are owned by company insiders. Comparatively, 2.7% of Oblong shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Black Titan has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Oblong has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Oblong | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Black Titan and Oblong”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | 93.43 | -$4.71 million | ($2.95) | -0.63 |
| Oblong | $2.38 million | 2.04 | -$4.04 million | ($1.71) | -0.88 |
Oblong has higher revenue and earnings than Black Titan. Oblong is trading at a lower price-to-earnings ratio than Black Titan, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Black Titan and Oblong’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Oblong | -187.17% | -62.63% | -52.38% |
Summary
Oblong beats Black Titan on 8 of the 11 factors compared between the two stocks.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
About Oblong
Oblong Inc., together with its subsidiaries, provides multi-stream collaboration technologies and managed services for video collaboration and network applications in the United States and internationally. The company operates in two segments, Collaboration Products and Managed Services. Its flagship product is Mezzanine that enables visual collaboration across multi-users, multi-screens, multi-devices, and multi-locations for video telepresence, laptop and application sharing, and whiteboard sharing and slides applications. The company also provides managed videoconferencing services; and remote service management, which provides an overlay to enterprise information technology and channel partner support organizations, as well as support and management services for customer video environments. In addition, it offers network services comprising Cloud Connect: Video that allows its customers to outsource the management of their video traffic to them and provides the customer’s office locations with a secure, dedicated video network connection to the Oblong Cloud for video communications; Cloud Connect: Converge, which offers customized multiprotocol label switching solutions; and Cloud Connect: Cross Connect that allows the customer to leverage existing carrier for the extension of a Layer 2 private line to its data center. Further, it provides professional services, such as software development, visual and interaction design, engineering, and project support services; and resells video equipment to its customers. Oblong Inc. is based in Conifer, Colorado.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
